Journal: Molecular medicine reports

Article Title: Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation.

doi: 10.3892/mmr.2015.3157

Figure Lengend Snippet: Figure 5. CXCL12, CCL21 and CXCL16 expression analysis. (A) Representative western blots for CXCL12, CCL21 and CXCL16. Semi‑quantitative analysis of protein expression levels of (B) CXCL12, (C) CCL21 and (D) CXCL16. Actin was used as an internal control. *P<0.05 vs. Sh; †P<0.05 vs. U+V and ‡P>0.05 vs. U+V. UUO, unilateral ureteral obstruction; Sh, control; U+V, UUO+vehicle; U+E1, UUO treated with 300 U/kg rhEPO; rhEPO, recombinant human erythropoietin; U+E2, UUO treated with 1,000 U/kg rhEPO; CXCL16, CXC chemokine ligand 16; CCL21, CC chemokine ligand 21.

Article Snippet: Proteins were electrophoretically transferred to nitrocellulose membranes (Millipore, Billerica, MA, USA) which were subsequently incubated with antibodies specific for α‐SMA (1:500), collagen I (1:1,000), fibronectin (1:400), CXCL12 (1:1,000) , CCL21 (1:600), CXCL16 (1:500) and β-actin (1:1,000), followed by incubation with secondary antibody conjugated with IRDye® infrared dye (Rockland Immunochemicals, Inc.).

Techniques: Expressing, Western Blot, Control, Recombinant